0 CHECKOUT

Bacterial Conjunctivitis - Pipeline Review, H1 2015

  • ID: 3259637
  • April 2015
  • 53 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Cellceutix Corporation
  • Ocular Therapeutix, Inc.
  • MORE

Bacterial Conjunctivitis - Pipeline Review, H1 2015

Summary

This, ‘Bacterial Conjunctivitis - Pipeline Review, H1 2015’, provides an overview of the Bacterial Conjunctivitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bacterial Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Cellceutix Corporation
  • Ocular Therapeutix, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Bacterial Conjunctivitis Overview
Therapeutics Development
Pipeline Products for Bacterial Conjunctivitis - Overview
Pipeline Products for Bacterial Conjunctivitis - Comparative Analysis
Bacterial Conjunctivitis - Therapeutics under Development by Companies
Bacterial Conjunctivitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bacterial Conjunctivitis - Products under Development by Companies
Bacterial Conjunctivitis - Companies Involved in Therapeutics Development
Cellceutix Corporation
China Grand Wuhan General Pharmaceutical Research Institute
Daiichi Sankyo Company, Limited
InSite Vision Incorporated
NovaBay Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Bacterial Conjunctivitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
auriclosene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brilacidin tetrahydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISV-405 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levofloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
moxifloxacin hydrochloride SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-638 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-704 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-727 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XY-0911AQ2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bacterial Conjunctivitis - Recent Pipeline Updates
Bacterial Conjunctivitis - Dormant Projects
Bacterial Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US
Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops
Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops
Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Bacterial Conjunctivitis, H1 2015
Number of Products under Development for Bacterial Conjunctivitis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Bacterial Conjunctivitis - Pipeline by Cellceutix Corporation, H1 2015
Bacterial Conjunctivitis - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H1 2015
Bacterial Conjunctivitis - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Bacterial Conjunctivitis - Pipeline by InSite Vision Incorporated, H1 2015
Bacterial Conjunctivitis - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015
Bacterial Conjunctivitis - Pipeline by Ocular Therapeutix, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Bacterial Conjunctivitis Therapeutics - Recent Pipeline Updates, H1 2015
Bacterial Conjunctivitis - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Bacterial Conjunctivitis, H1 2015
Number of Products under Development for Bacterial Conjunctivitis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Cellceutix Corporation
China Grand Wuhan General Pharmaceutical Research Institute
Daiichi Sankyo Company, Limited
InSite Vision Incorporated
NovaBay Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Alcon Incorporated
  • Bausch & Lomb, Inc.
  • Essilor International S.A.
  • Johnson & Johnson Services, Inc.
  • Specsavers Optical Group Ltd.
  • Luxottica Group